Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019549HBVENSG00000182578.14protein_codingCSF1RNoNo1436P07333
TVIS10036143HBVENSG00000182578.14protein_codingCSF1RNoNo1436P07333
TVIS10062766HBVENSG00000182578.14protein_codingCSF1RNoNo1436P07333
TCGA Plot Options
Drug Information
GeneCSF1R
DrugBank IDDB00619
Drug NameImatinib
Target IDBE0000853
UniProt IDP07333
Regulation Typeantagonist
PubMed IDs15917650; 16170366; 16449525; 16816921; 17049513
CitationsDewar AL, Zannettino AC, Hughes TP, Lyons AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005 Jul;4(7):851-3. Epub 2005 Jul 28.@@Taylor JR, Brownlow N, Domin J, Dibb NJ: FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006 Jan 5;25(1):147-51.@@Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC: Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006 Jun 1;107(11):4334-7. Epub 2006 Jan 31.@@Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab. 2006;24(4):274-82.@@El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S: Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol. 2006 Dec 3;551(1-3):27-33. Epub 2006 Sep 16.
GroupsApproved
Direct ClassificationBenzanilides
SMILESCN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
PathwaysImatinib Inhibition of BCR-ABL
PharmGKBPA10804
ChEMBLCHEMBL941